In addition, prior studies examining RNA-electroporated mesothelin-directed CAR T cells in patients with malignant pleural mesothelioma and pancreas cancer demonstrated the potential of systemically infused mRNA CAR T cells to traffick into the tumor microenvironment and induce disease stability and clinical response (38, 39). This evidence concerns the gene MSLN and malignant pleural mesothelioma.